Daniele Robesti

Urology resident @Unisr

[Alberto Martini @AlbertoMartini_]

More research on the topic on its way! Also presented at #EAU26

https://t.co/gwbnVWsNI7

@DRobesti @GFallara_MD @UroDocAsh @GPloussard

[Alberto Martini @AlbertoMartini_]

Exciting progress in BCG-unresponsive NMIBC. Our @TheLancetOncol commentary explores the promise of cretostimogene, balancing impressive durability and safety data with the key questions that still need answers.

https://t.co/UhOKACeUJE

[Alberto Martini @AlbertoMartini_]

EV-302 reshaped the landscape of metastatic urothelial carcinoma.
However, two critical methodological aspects warranted deeper scrutiny and were addressed in our recent paper:
https://t.co/nR2JD6RRE4

[Alberto Martini @AlbertoMartini_]

Chech out our study on TMT vs. RC for #MIBC a (long) 🧵(with some stats)

https://t.co/Z3G1ySwXFr

@CHematology @DRobesti @GPloussard @GFallara_MD
@uofcincycancer @OncoAlert @OncLiveSOSS @Uroweb @EauGuidelines @AmerUrological @UroOnc

[Daniele Robesti @DRobesti]

@onder_haka2124 @DrYukselUrun @CHematology @ChristianRolfo @OncoAlert @achoud72 @gbanna74 @PGrivasMDPhD @shilpaonc @ERPlimackMD @drenriquegrande @SuyogCancer @cdanicas @yekeduz_emre Reverse KM after IC adjustment for OS — modeling was performed for all outcomes except CSS (no imbalance), but HR quantification post-adjustment was done only for OS

[Daniele Robesti @DRobesti]

@onder_haka2124 @DrYukselUrun @CHematology @ChristianRolfo @OncoAlert @achoud72 @gbanna74 @PGrivasMDPhD @shilpaonc @ERPlimackMD @drenriquegrande @SuyogCancer @cdanicas @yekeduz_emre Table 2 and Figure 2 are pre-adjustment.

[Yüksel Ürün @DrYukselUrun]

Most retrospective studies comparing trimodal therapy and radical cystectomy are at high risk of informative censoring a bias that can artificially favor one treatment over another. @CHematology @ChristianRolfo @OncoAlert
https://t.co/HI0hcXAuGl

[Daniele Robesti @DRobesti]

@onder_haka2124 @DrYukselUrun @CHematology @ChristianRolfo @OncoAlert @achoud72 @gbanna74 @PGrivasMDPhD @shilpaonc @ERPlimackMD @drenriquegrande @SuyogCancer @cdanicas @yekeduz_emre Appreciate your point on the risks of asymmetric IC correction — totally agree it's a key issue in comparative effectiveness. Just to clarify: in the recent manuscript, IC was evaluated and modeled for both TMT and RC, with simulations showing bias could favor either treatment.

[Daniele Robesti @DRobesti]

And finally... Thank you @eug20miglia !!!

[Daniele Robesti @DRobesti]

🔬 Our latest study dives into laser lithotripsy with a novel in-vitro setup to explore thermal effects. Using a glass pipette model of a renal calyx, we measured temperature changes and thermal doses under varied conditions. #UrologyResearch #MedicalInnovation

[Daniele Robesti @DRobesti]

📊 Results are in: Higher laser power correlates with increased thermal risk. Maintaining a 'thermal safety distance' effectively reduces the likelihood of tissue damage. Recommended power: ≤10W in the ureter, ≤20W in the kidney with irrigation. #Urology #PatientSafety

[Daniele Robesti @DRobesti]

🌡️ By integrating thermal camera images and the Sapareto-Dewey formula, we quantified the safe distances from laser fiber to prevent tissue damage. #Thermalsafety #Urology